Retaining the UK as a Leader in Cell & Gene Therapy: A Call To Action
Our latest report examines the global trends and drivers nourishing the growth of CGT and the implications for real estate.
- Chris Walters
- George Beaton
Despite the economic uncertainties, the UK Life Sciences industry 1 has continued to see significant growth over the last few years, supported by its prominent role in the COVID-19 pandemic, as well as macro drivers around an ageing general population, health-focused demographics, and increased disposable incomes.
Whilst venture capital investment and other growth indicators moderated in 2022, certain subsectors within the industry continue to go from strength to strength. One example is cell and gene therapy (CGT), where there was a 22% CAGR in company numbers between 2015-2021 in the UK alone2 . These advanced therapies and technologies are driving innovation and medical capabilities – and will likely have stark impacts on the real estate requirements in the UK in the coming years.
This report examines the global trends and drivers nourishing the growth in CGT, its UK geography, and the implications for real estate, both R&D and general manufacturing, drawing on relevant success stories. It is first and foremost a call to action highlighting the existing world leading status of the UK in CGTs and the need to accommodate future growth if the UK is to remain a global leader.
[1] https://www.jll.co.uk/en/trends-and-insights/research/emea-life-sciences-cluster-outlook-2023
[2] Office for Life Sciences, JLL Research
